

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on February 22, 2007

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

ELECTION UNDER 35 U.S.C. §121
Examining Group 1635
Patent Application
Docket No. USF-T187XC1
Serial No. 10/734,548

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Dana H. Shin
Art Unit : 1635
Applicants : Shyam S. Mohapatra, Homero Gabriel San Juan Vergara
Serial No. : 10/734,548
Filed : December 12, 2003
For : Protein Kinase C as a Target for the Treatment of Respiratory Syncytial Virus

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ELECTION UNDER 35 U.S.C. §121


Sir:

In response to the written restriction requirement dated January 30, 2007, the applicants hereby elect interfering RNA (claims 21 and 22) as the single PKC inhibitor.

A Preliminary Amendment is being submitted with this Election. The elected invention encompasses new claims 23-27. Accordingly, the applicants respectfully request that new claims 23-27 be examined in the subject application.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
P.O. Box 142950
Gainesville, FL 32614-2950

GPL/mv

Attachment: Preliminary Amendment